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Abstract
Background: Extramedullary plasmacytoma is a rare neoplasm characterized by monoclonal proliferation of plasma
cells outside bone marrow. It accounts for 4% of all non-epithelial sinonasal tumors. According to the literature,
radiotherapy is the standard therapy for extramedullary plasmacytoma. However, the conversion rate of
extramedullary plasmacytoma to multiple myeloma is reported to be between 11 and 33% over 10 years.
The highest risk of conversion is reported during the first 2 years after diagnosis, but conversion has been
noted up to 15 years after diagnosis. Once conversion to multiple myeloma is complete, less than 10% of
patients will survive 10 years.
Case presentation: We present three cases of sinonasal extramedullary plasmacytoma who underwent radiotherapy:
a 61-year-old white man, a 60-year-old white man, and a 37-year-old white woman. We found long-term survival with
stable disease in all three cases.
Conclusions: The management of solitary extramedullary plasmacytomas of the sinonasal tract is not well established
yet. However, the possibility of recurrence and progression to multiple myeloma requires a thorough follow-up
protocol. Due to the absence of a standardized protocol for these tumors, we tried to design a tailored long-term
follow-up scheme.
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Background
Plasmacytoma is a malignant neoplasm of monoclonal B
cells first described by Schridde in 1905 [1]. It consists
of three distinct entities according to the International
Myeloma Working Group, 2003: solitary plasmacytoma
of bone (SPB), extramedullary plasmacytoma (EMP),
and multiple primary or recurrent plasmacytomas
(Table 1) [2, 3].
EMP accounts for less than 4% of all plasma cell tumors
and represents 1% of all head and neck tumors [4–6].
More than 80% of plasma cell tumors are localized in the
upper aero-digestive tract with approximately 80% within
the sinonasal cavity [4–6]. In general, the median age at
diagnosis of EMP is 55 to 60 years with a male/female ra-
tio of 3:1 [7]. Only a few cases of EMP (15 to 20%) pro-
gress to multiple myeloma (MM) [4]; however, despite
recent advances in laboratory, imaging, and clinical evalu-
ation, it is still impossible to identify which cases of EMP
progress to MM [5].
Nasal obstruction, usually unilateral, is the most com-
mon presenting symptom of sinonasal EMP; however, it
is observed in only 29.8% of cases [8]. Other commonly
presenting symptoms are epistaxis, facial swelling, pain,
and rhinorrhea [5]. The presence of cervical lymph
nodes involvement at diagnosis ranges from 5 to 20% of
cases [5].
A biopsy of the tumor is required to confirm the diag-
nosis of EMP [7, 9]. It is based on the morphologic and
immunophenotypic findings of localized monoclonal
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plasma cells in the absence of plasma cells proliferation
in other sites, especially in the bone marrow, and in the
absence of malignant lymphoma [5]. CD138 is the most
useful plasma cell marker [7].
Although different therapeutic approaches have been
proposed in the literature, due to its high radiosensitiv-
ity, radiotherapy represents the treatment of choice for
EMP [1, 5]. However, complete surgical excision is sug-
gested only in small localized lesions, while the role of
chemotherapy still remains unclear [7].
In this article we reported a series of three sinona-
sal EMPs (two men, one woman; mean age 53, range
37 to 61) aiming to clarify some diagnostic and thera-
peutic aspects.
Case presentation
Case 1
A 61-year-old white man complained of diffuse right
maxillary sinus pain, ipsilateral epistaxis, and rhinorrhea
for 4 months. A complete basal serum work-up was nor-
mal, including serum and urine protein electrophoresis.
A nasal endoscopy showed a bloody tumor mass occu-
pying his right nasal cavity; at clinical examination no
palpable laterocervical lymph nodes were found.
A computed tomography (CT) scan revealed the pres-
ence of soft tissue involving his right maxillary sinus
extending into the ipsilateral nasal cavity with size
greater than 4 cm. Signs of bone erosion were observed
at the level of alveolar superior bone, with osteolytic area
of 2.5 cm extended to his nasal septum.
Magnetic resonance imaging (MRI) with contrast
medium showed hyperintense signal in T1 and fluid-
attenuated inversion recovery (FLAIR) sequences and
hypointense signal in T2 in his right maxillary sinus
and nasal fossa.
A nasal biopsy performed under local anesthesia
allowed the diagnosis of EMP. An immunohistochemical
study showed diffuse positivity for CD138 with immuno-
globulin (Ig) kappa light chain restriction. An iliac crest
needle biopsy did not demonstrate bone marrow in-
volvement; total body sestamibi scintigraphy showed
normal tracer uptake in bones and soft tissues.
He underwent radiotherapy with a total dose of 60 Gy,
by linear accelerator, with complete disappearance of
disease, but after 5 years he presented with a local recur-
rence confirmed by a biopsy of the lesion. He was then
treated with chemotherapy based on thalidomide and
dexamethasone without any response. He received further
treatment with bortezomib/dexamethasone followed by
autologous bone marrow transplantation. However, he ex-
perienced a further relapse 1 year later: he was treated
with lenalidomide and dexamethasone, with partial and
stable remission. After 13 years, he is still alive with signs
of stable local disease.
Case 2
A 60-year-old white man complained of right nasal
respiratory obstruction and ipsilateral epistaxis and rhi-
norrhea. No abnormalities were evident by basal serum
work-up, including serum and urine protein electrophor-
esis. A nasal endoscopy showed a bloody tumor mass
occupying his right nasal cavity (Fig. 1); at clinical exam-
ination no palpable laterocervical lymph nodes were
found.
A CT scan revealed a soft tissue involving his right
nasal cavity, extending into the ipsilateral ethmoid sinus,
Table 1 International Myeloma Working Group diagnostic criteria of solitary plasmacytoma of bone, extramedullary plasmacytoma,
and multiple solitary plasmacytomas (primary or recurrent) [3]
Diagnosis Criteria
Solitary plasmacytoma of bone (SPB) No M-protein in serum and/or urine*
Single area of bone destruction due to clonal plasma cells
Bone marrow not consistent with multiple myeloma (plasma cells <5%)
Normal skeletal survey (and magnetic resonance imaging of spine and pelvis if done)
No related organ or tissue impairment (no end organ damage other than solitary bone lesion)*
Extramedullary plasmacytoma (EMP) No M-protein in serum and/or urine*
Extramedullary tumor of clonal plasma cells
Normal bone marrow
Normal skeletal survey
No related organ or tissue impairment (end organ damage including bone lesions)*
Multiple solitary plasmacytomas
(primary or recurrent)
No M-protein in serum and/or urine*
More than one localized area of bone destruction or extramedullary tumor of clonal plasma cells
which may be recurrent
Normal bone marrow
Normal skeletal survey and magnetic resonance imaging of spine and pelvis if done
No related organ or tissue impairment (no end organ damage other than the localized bone lesions)
*A small M-component may sometimes be present
Modified by International Myeloma Working Group. “Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report
of the International Myeloma Working Group.” Br J Haematol 2003;121:749–57 [3]
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not easy to excise with dimensions greater than 3.5 cm.
No signs of bone erosion were observed (Fig. 2).
MRI with contrast medium showed hyperintense sig-
nal in T1 and FLAIR sequences and hypointense signal
in T2 in the right nasal fossa (Fig. 3).
A nasal biopsy performed under local anesthesia
allowed diagnosis of EMP. Morphological, immunophe-
notypic, and immunohistochemical findings confirmed
the presence of EMP with a diffuse reactivity for CD138.
An iliac crest needle biopsy did not demonstrate bone
marrow involvement, total body sestamibi scintigraphy
showed normal tracer uptake in bones and soft tissues.
He underwent radiotherapy with a total dose of 40 Gy
showing a total response without significant side effects.
After 5 years he presented with recurrence localized to
the left humerus bone, which was treated with radiother-
apy with a total dose of 20 Gy, followed by autologous
bone marrow transplantation. Three years later, a new
recurrence to his right clavicle was treated with radio-
therapy with total dose of 40 Gy and a further
localization to his right hip appeared 1 year later and
was treated with radiotherapy with total dose of 40
Gy followed by maintenance chemotherapy with thal-
idomide and dexamethasone with partial therapeutic
response. After 12 years, is still alive with stable signs
of local disease.
Case 3
A 37-year-old white woman complained of left nasal re-
spiratory obstruction. A monoclonal spike in serum as
well as monoclonal Bence Jones protein in the urine
electrophoresis were absent. Her renal functions, liver
functions, and blood profile were normal. A nasal endos-
copy showed a bloody tumor mass occupying her left
nasal cavity; at clinical examination no palpable latero-
cervical lymph nodes were found.
CT and MRI revealed a mass involving her left
maxillary sinus and the ipsilateral nasal cavity (size
approximately 5 cm).
A nasal biopsy performed under local anesthesia con-
firmed the diagnosis of EMP. Immunohistochemical
evaluation showed diffuse reactivity for CD138 with
kappa light chain restriction. An iliac crest needle biopsy
did not demonstrate bone marrow involvement.
She underwent radiotherapy for a total dose of 40 Gy,
but due to progression of disease 6 months later, she
underwent four cycles of chemotherapy according to the
vincristine, adriamycin, and dexamethasone (VAD) scheme
with only a partial response. After 2 years, because of sys-
temic disease progression, she again received three cycles
of chemotherapy according to the VAD scheme and au-
tologous bone marrow transplantation, obtaining complete
disease remission. After 12 years, she is still alive and in
disease remission.
Fig. 1 Nasal endoscopy of Case 2. Nasal endoscopy showed a bloody
tumor mass occupying the right nasal cavity
Fig. 2 Computed tomography of Case 2. Computed tomography scan, axial view, revealed a soft tissue involving the right nasal cavity (a; white arrow),
extending into the ipsilateral ethmoid sinus (b; white arrow). No signs of bone erosion were observed
Cantone et al. Journal of Medical Case Reports  (2017) 11:219 Page 3 of 6
Discussion
EMP is a rare plasma cell neoplasm which involves soft
tissues, without systemic involvement. It most frequently
occurs in the upper respiratory tract and oral cavity
(Table 2) [2, 4, 5, 7, 10]. Since EMP can have different
clinical and therapeutic features, the diagnosis of EMP
and the choice of the treatment should be discussed
by a multidisciplinary cancer board including an oto-
laryngologist, an oncohematologist, a pathologist, and
a radiotherapist.
In addition to biopsy and histological examination,
EMP diagnostic procedures should comprise laboratory
studies including serum and urine protein electrophor-
esis, quantitative Ig and beta-2-microglobulin determin-
ation in serum, complete nasal endoscopic examination,
extensive imaging study (CT, MRI), and functional tests
such as 18F-fluorodeoxyglucose-positron emission tom-
ography (FDG-PET) or sestamibi scintigraphy. EMP
must be distinguished from reactive plasma cell lesions
and lymphoma. The diagnosis of EMP is based on
monoclonal plasma cells infiltrate without B cell compo-
nent. Monoclonality and/or an aberrant plasma cell
phenotype should be demonstrated with useful immuno-
phenotypic markers such as CD138, CD38, kappa/λ light
chain ratio, CD19, CD56, CD27, CD117, and cyclin
D1 [11].
Furthermore, bone marrow biopsy and/or needle
aspiration is of utmost importance to determine the
percentage of plasma cells, which should be less than
5% [1].
Regarding the natural history of the disease, Batsakis
[12] defined five possible stages that EMP can present:
I. Localized disease; solitary, controlled by surgery,
radiotherapy, or both; without recurrence or
dissemination.
II. Disease with local recurrence controlled by
additional therapy.
Fig. 3 Magnetic resonance imaging with contrast of Case 2. Magnetic resonance imaging, axial view, with contrast medium showed hyperintense
signal in T1 (a; white arrow) and fluid-attenuated inversion recovery sequences and hypointense signal in T2 (b; white arrow) in the right nasal fossa
Table 2 Extramedullary plasmacytoma cases of nasal and paranasal sinuses reported in the English language literature
Reference Pt Age/Sex Site Symptoms Treatment Recurrence Mts Follow-up
Ashraf et al. 2013 [7] 3 43/M Nasal cavity Nasal obstruction, epistaxis RT+surgery
Surgery+RT (44 Gy)
RT
No
No
No
No
No
No
1 year
1 year
3 years
Corvo et al. 2013 [13] 1 51/F Nasal cavity/maxillary
sinus
Nasal obstruction,
epistaxis
RT (48 Gy)+surgery No No 6 years
Verim et al. 2014 [10] 1 69/F Frontal sinus (4×3 cm) Chronic headache Surgery+RT (40 Gy) No No 18 months
D’Aguillo et al. 2014 [8] 175 55/
M:F of 2.3:1
M (69.4%)
F (30.6%)
Nasal cavity/septum
(32.5%),
maxillary sinus (26.8%),
nasopharynx (18.6%),
ethmoid sinus (7.2%),
sphenoid sinus (6.7%),
paranasal sinus (6.2%),
frontal sinus (2.1%)
Nasal obstruction (29.8%),
epistaxis (24.2%),
facial swelling (9.9%),
facial pain (9.9%),
painless mass (6.8%),
change or loss of vision
(6.2%),
nasal discharge (4.3%),
CN VI palsy (3.7%),
proptosis/ptosis (2.5%),
headache (2.5%)
RT (50.9%),
surgery+RT (21.7%),
surgery (14.3%),
CHT (1.7%),
RT+CHT (5.1%),
RT+Surgery+CHT
(3.4%),
no therapy (2.9%)
16% No 39–60.9
months
CHT chemotherapy, CN VI palsy sixth cranial nerve, F female, M male, Mts metastases, Pt patients, RT radiotherapy
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III. Aggressive disease, persistent or recurrent; death by
uncontrollable local extension.
IV. Local disease with regional lymph node “metastasis”
without evidence of distant spread.
V. Local disease, recurrent or followed by
dissemination and development of another neoplasm
of plasma cells and/or MM [13].
Following this classification all three of our patients
are in stage V.
According to the literature, the gold standard therapy
for EMP is radiotherapy [5, 8]. In fact, solitary EMPs
smaller than 5 cm have an excellent local control with
radiation doses of 30 to 40 Gy in 20 fractions, whereas
tumors larger than 5 cm may require higher doses (40 to
50 Gy) [5]. Cervical nodes should be included if involved
[5]. Overall, most studies report high local control rates
of approximately 80 to 100% with moderate doses [14].
Chemotherapy is considered only in patients with tumors
larger than 5 cm, high-grade tumors, refractory and/or re-
lapsed disease, and in case of progression to MM [1, 15].
Only in small localized cases is complete surgical excision
appropriate [5]. However, when clear surgical margins are
obtained, the rate of local control with surgery alone is
similar to that achieved with radiotherapy alone. Instead,
radiotherapy followed by surgical excision is often
employed to reduce the tumor volume and consequently
the invasiveness of surgery [5].
Since head and neck plasma cell neoplasms can be
very aggressive with a high tendency to local recurrence,
it is important to adequately irradiate all cancer cells
with enough doses to ensure tumor control. On the other
hand, healthy tissues are very sensitive to radiation. For in-
stance, salivary glands, larynx, and constrictor muscles
can be particularly damaged by radiotherapy resulting in
long-term sequelae with an incidence of acute as well as
late side effects, especially regarding skin toxicity, mucosi-
tis, xerostomia, dry-eye syndrome, radiation-induced
retinopathy, and neovascular glaucoma, lacrimal duct
stenosis, brain necrosis, and osteoradionecrosis of the
maxilla [5].
The long-term survival rate reported in the literature
[8], the presence of long-term stable disease as observed
in our patients, and the possibility of late recurrences
suggest the need of long-term follow-up.
A recent systematic review of 175 sinonasal EMPs by
D’Aguillo et al. [8] confirmed a higher occurrence of
these neoplasms in men, with a male to female ratio of
2.3:1. They found that the mean age of diagnosis was 55
years, with a range of 5 years to 79 years. Moreover, they
showed that a sinonasal EMP most often recurs as a
space-occupying lesion. They found that nasal obstruction
was the most common presenting symptom (29.8% of 175
cases). Other commonly cited presenting symptoms
included epistaxis (24.2%), facial swelling (9.9%), facial
pain (9.9%), painless mass (6.8%), and change or loss of
vision (6.2%). The development of MM is a known seque-
lae of EMP. The rate of conversion of EMP to MM is
lower than other plasma cell neoplasms, such as SPB, with
rates reported to be between 11 and 33% over 10 years
[8]. The highest risk of conversion is in the first 2 years
after diagnosis, but conversion has been noted up to 15
years after diagnosis. Once conversion to MM is complete,
less than the 10% of patients will survive 10 years. In the
recent review published by D’Aguillo et al. [8], 16 patients
(9.1%) converted to MM, with a median follow-up of 39
months (3.25 years). Eleven of these 16 patients (68.8%)
died because of their disease. So it is recommended that
patients receive regular follow-up after diagnosis of EMP
due to the relatively high risk of conversion.
The rarity of the tumor, the lack of randomized clinical
trials, and the propensity toward case reports create a
debate regarding the optimal follow-up protocol for soli-
tary EMPs of the sinonasal tract, which continues to be
ambiguous.
Myeloma Guidelines by the Italian Association of
Medical Oncology (AIOM) [16] suggest the first
screening 45 to 60 days after radiotherapy by serum
examinations, then every 3 months for the first year,
subsequently every 6 months by serum, radiological,
and bone marrow examinations, if necessary. Due to
the high risk of conversion, D’Aguillo et al. [8] pro-
posed a regular screening for MM every 6 weeks for
the first 6 months after diagnosis of EMP and then
periodically, but without a specific timing. For these
reasons, we propose a follow-up protocol consisting
of nasal endoscopy and serum examinations every 3
months, and imaging study with MRI 3 months after
radiotherapy and subsequently every 6 months per
year for 5 years; after 5 years, we propose serum
examinations and nasal endoscopy every 6 months
and MRI every year. We recommend a biopsy only in
cases of clinical and instrumental suspicion of
recurrence.
Conclusions
In conclusion, due to the rarity, sites, clinical history,
proximity of critical structures, as well as long-term
stable disease survival, we believe that the diagnostic ap-
proach to EMP should be multidisciplinary and the
treatment considered case by case, confirming, in our
experience, radiotherapy as the therapy of choice. Ac-
cording to the literature, we observed a high (10 years)
survival rate. This aspect, in addition to the possibility of
recurrence and the relatively high risk for conversion to
MM, prompts a thorough follow-up protocol that, in
our opinion, should be designed as described.
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